A registry of HLA‐typed donors for production of virus‐specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune‐compromised patients

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Transfusion

• Publication date

  2014-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/trf.12754PMID 25041366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.

  2013cited by this paper
• Antiviral cell therapy: is this the future?

  2013cited by this paper
• Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.

  2013cited by this paper
• CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.

  2013cited by this paper
• Improving T-cell therapy for epstein-barr virus lymphoproliferative disorders.

  2013cited by this paper
• Epstein‐Barr virus, B cell lymphoproliferative disease, and SCID mice: Modeling T cell immunotherapy in vivo

  2011cited by this paper
• High Throughput T Epitope Mapping and Vaccine Development

  2010cited by this paper
• Infections in Recipients of Hematopoietic Cell Transplantation

  2010cited by this paper
• Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

  2010cited by this paper
• Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

  2010cited by this paper
• Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)

  2010cited by this paper
• Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

  2010cited by this paper
• Viral Infections in Immunocompromised Patients

  2010cited by this paper
• Adoptive transfer of virus-specific and tumor-specific T cell immunity.

  2009cited by this paper
• Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host.

  2009cited by this paper
• Epstein-Barr Virus

  2009cited by this paper
• Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

  2009cited by this paper
• Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy

  2009cited by this paper
• A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

  2008cited by this paper
• Evaluation of Antigen-Specific T-Cell Responses with a Miniaturized and Automated Method

  2008cited by this paper
• Cytotoxic T lymphocytes as immune‐therapy in haematological practice

  2008cited by this paper
• Positive Selection and Expansion of Cytomegalovirus-specific CD4 and CD8 T Cells in Sealed Systems: Potential Applications for Adoptive Cellular Immunoreconstitution

  2008cited by this paper
• Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.

  2008cited by this paper
• CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.

  2008cited by this paper
• Exploiting Cytokine Secretion to Rapidly Produce Multivirus-specific T Cells for Adoptive Immunotherapy

  2008cited by this paper
• Clinical Grade Generation of Hexon-specific T Cells for Adoptive T-cell Transfer as a Treatment of Adenovirus Infection After Allogeneic Stem Cell Transplantation

  2008cited by this paper
• Five donors–one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors

  2008cited by this paper
• Helper function of cytolytic lymphocytes: Switching roles in the immune response

  2007cited by this paper
• Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

  2007cited by this paper
• High throughput functional microdissection of pathogen-specific T-cell immunity using antigen and lymphocyte arrays.

  2007cited by this paper
• Generation of Trispecific Cytotoxic T Cells Recognizing Cytomegalovirus, Adenovirus, and Epstein-Barr Virus: An Approach for Adoptive Immunotherapy of Multiple Pathogens

  2007cited by this paper
• In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes.

  2006cited by this paper
• Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus.

  2006cited by this paper
• Safe adoptive transfer of virus‐specific T‐cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation

  2006cited by this paper
• Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

  2006cited by this paper
• Successful In Vitro Priming of EBV‐Specific CD8+ T Cells Endowed with Strong Cytotoxic Function from T Cells of EBV‐Seronegative Children

  2006cited by this paper
• Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

  2006cited by this paper
• Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation.

  2005cited by this paper
• Cellular immunotherapy for viral infection after HSC transplantation

  2005cited by this paper
• Generation of cytomegalovirus (CMV)-specific CD4 T cell lines devoid of alloreactivity, by use of a mixture of CMV-phosphoprotein 65 peptides for reconstitution of the T helper repertoire.

  2005cited by this paper
• Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer.

  2005cited by this paper
• Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy.

  2004cited by this paper
• Establishment and Characterization of a Bank of Cytotoxic T Lymphocytes for Immunotherapy of Epstein-Barr Virus-Associated Diseases

  2004cited by this paper
• CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection

  2004cited by this paper
• Clinical aspects of CMV infection after stem cell transplantation.

  2004cited by this paper
• Identification of new Th peptides from the cytomegalovirus protein pp65 to design a peptide library for generation of CD4 T cell lines for cellular immunoreconstitution.

  2004cited by this paper
• Helping the CD8+ T-cell response

  2004cited by this paper
• Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

  2003cited by this paper
• Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.

  2002cited by this paper
• Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.

  2002cited by this paper
• Safety of allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T lymphocytes for patients with refractory EBV‐related lymphoma

  2002cited by this paper
• Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals1

  2002cited by this paper
• Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.

  2001cited by this paper
• Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients.

  2001cited by this paper
• Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.

  1999cited by this paper
• Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

  1998cited by this paper
• Adoptive cellular immunotherapy for EBV lymphoproliferative disease.

  1997cited by this paper
• Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts

  1997cited by this paper
• Adoptive cellular immunotherapy for EBV lymphoproliferative diseases

  1997cited by this paper
• Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

  1995cited by this paper
• Principles for adoptive T cell therapy of human viral diseases.

  1995cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Lymphocytes

  1991cited by this paper
• Respiratory Syncytial Virus

  1988cited by this paper
• Principles and practice of infectious diseases. Vols 1 and 2.

  1979cited by this paper

• Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?

  2025cites this paper
• Development and characterization of a cell donor registry for virus‐specific T cell manufacture in a blood bank

  2024cites this paper
• Third-Party-T-Zell-Spender: eine alternative Quelle virusspezifischer T-Zellen für die adoptive Immuntherapie

  2016cites this paper
• Recent advances in treatment of severe primary immunodeficiencies

  2015cites this paper
• Chemotherapy Necessitates Increased Immune Control of HHVs: A Cause of Persistent Inflammation Enabling Protracted Fatigue in Breast Cancer Survivors

  2013cites this paper
• TITLE: Chemotherapy necessitates increased immune control of HHVs: A cause of persistent inflammation enabling protracted fatigue in breast cancer survivors

  2013cites this paper